IPO Timeline
Broker Results (T-2)
2021-11-03
Some brokers release in afternoon
Grey Market (T-1)
2021-11-04
Afternoon
HKEX Allotment (T-1)
2021-11-04
Evening
Registrar Allotment (T-1)
2021-11-04
Evening
Listing Day (T)
2021-11-05
First day of trading
Company Overview
| Stock Name | 三葉草生物製藥有限公司 - B |
|---|---|
| Stock Code | 02197 |
| Company Full Name | 三葉草生物製藥有限公司 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，為傳染性疾病、癌癥及自身免疫性疾病開發新型疫苗及生物治療候選產品。 |
| Listing Date | 2021-11-05 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國四川省成都市自由貿易試驗區成都高新區天府大道北段1480號高新孵化園1號樓B5-19 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.cloverbiopharma.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 13.38 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 53.7% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 200,700,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 12.98 |
|---|---|
| First Day Open | HK$ 13.38 |
| First Day Change | -2.99% |
| First Day Volume | 33982000.0 |
| First Day Turnover | 448171000.0 |
Use of Proceeds
| Use of Proceeds | 約65%，或1,215.6百萬港元將用于我們核心產品及相關產品的研發、生產及商業化； 約22.5%，或420.8百萬港元將用于我們管線中其他產品的研發、生產及商業化； 約12.5%，或233.8百萬港元將用作營運資金及其他一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (3)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (3)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Lead Managers (3)
高盛（亚洲）有限责任公司 CE ACC536
中国国际金融香港证券有限公司 CE AEN894
Credit Suisse (Hong Kong) Limited CE AAO017
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Aranda Investments Pte. Ltd. | 155,589,330 HKD | — | 7.80% | — | 6 months | 2022-05-05 |
| 2 | Athos Asia Event Driven Master Fund | 116,686,980 HKD | — | 5.80% | — | 6 months | 2022-05-05 |
| 3 | Hillhouse Funds | 171,143,580 HKD | — | 8.50% | — | 6 months | 2022-05-05 |
| 4 | Oceanpine Capital Management Limited | 116,686,980 HKD | — | 5.80% | — | 6 months | 2022-05-05 |
| 5 | OrbiMed Funds | 194,484,990 HKD | — | 9.70% | — | 6 months | 2022-05-05 |
| 6 | Rock Springs Capital Master Fund LP | 147,808,860 HKD | — | 7.40% | — | 6 months | 2022-05-05 |
| 7 | Springhill Master Fund Limited | 77,791,320 HKD | — | 3.90% | — | 6 months | 2022-05-05 |
| 8 | Superstring Capital Master Fund LP | 58,343,490 HKD | — | 2.90% | — | 6 months | 2022-05-05 |
| 9 | Toroa Master Fund | 38,895,660 HKD | — | 1.90% | — | 6 months | 2022-05-05 |
Directors & Management
| Chairman | 梁朋 |
|---|---|
| Company Secretary | 王曉艷;周慶齡 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 梁朋(17.81%);Hillhouse Investment Management, Ltd.(12.73%);汪世碧及關連人士(8.67%);Super Novel International Limited(5.99%) |
|---|
IPO Timeline
